POM Expands U.S. Market with AI-Driven Healthcare Solutions

Pomdoctor, LTD. (NASDAQ: POM) is Expanding U.S. Market Presence with Healthcare Payers, Providers and Others to Progressively Scale Toward Broader Deployment Across Regional Markets

Pomdoctor, LTD. (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions, has announced significant progress in its strategy to expand its market presence in the United States. The company has been actively engaging with healthcare payers, providers, and other stakeholders to progressively scale its operations across regional markets.

POM has completed multiple rounds of optimization of its AI-enabled chronic disease management system, leveraging multidimensional real-world healthcare data, including medication, diagnosis and treatment, patient behavioral, monitoring, and healthcare payment data. The system will continue to evolve across key capabilities, including risk identification, personalized chronic disease intervention, and physician-patient follow-up workflows.

POM is also advancing the commercial application of its real-world data (RWD) capabilities through pharmaceutical real-world studies (RWS), evidence-based research cooperation, B2B healthcare data services, and chronic disease management collaborations with third-party healthcare institutions. The RWD ecosystem includes physiological, medication, behavioral, remote patient monitoring, and insurance-related data, providing a multidimensional foundation for healthcare research, patient management, and other commercial applications.

POM has participated in the 28th Annual H.C. Wainwright Global Investment Conference, held September 14 through September 16, 2026, at the Lotte New York Palace Hotel in New York City. The company's presentation was made available on its website at ir.7shiliu.com/Event-Calendar.

POM has also announced the formal initiation of its U.S. market entry preparations, marking a decisive advancement in its global growth strategy. As part of the initiative, POM has commenced recruitment for core U.S.-based leadership and operational roles, completed an initial assessment of the U.S. healthcare market, and begun structuring a dedicated local compliance and regulatory framework. Concurrently, POM is advancing product localization efforts and engaging in exploratory discussions with potential U.S. partners across the healthcare sector.

POM's U.S. expansion will follow a disciplined, multi-phase approach. The initial stage centers on pilot validation, including potential applications in remote patient monitoring (RPM) and chronic disease management. Upon successful pilot outcomes, POM intends to deepen engagement with healthcare payers, healthcare providers, and other ecosystem players, before progressively scaling toward broader commercial deployment across selected regional markets.

POM is a China-based online medical services platform focused on chronic disease management and pharmaceutical services. It operates an internet hospital plus pharmaceutical supply chain model that connects patients, doctors, and medicines. In more recent communications, POM has framed a longer-term strategic direction around AI-enabled predictive healthcare infrastructure (wearables, data, physician services, and payment networks), while still repeating the same core mission language in official materials.

POM's differentiated "hardware + AI + payment" infrastructure model seeks to consolidate capabilities that are typically fragmented across different digital health categories. The model is designed to integrate continuous health monitoring, AI-powered analysis, physician intervention, healthcare payment, and fulfillment within a unified, closed-loop ecosystem. This integrated model offers three distinct core advantages: a robust physician network, a proprietary wearable device gateway, and native integration with healthcare payment networks.

POM's mission is to provide effective prevention and treatment solutions to alleviate patients' sufferings from illnesses. The company's vision is to become the most trustworthy medical and healthcare services platform. POM's proven proprietary healthcare platform, extensive physician network, proprietary AI algorithms, wearable technologies, and solid real-world data infrastructure have been clinically validated and iteratively enhanced in the Chinese market.

POM's participation in the H.C. Wainwright Global Investment Conference with a virtual presentation available on its website underscores its commitment to advancing its AI-enabled chronic disease management and real-world data commercialization infrastructure. The company's U.S. market entry preparations and multi-phase approach demonstrate its strategic focus on expanding its operations globally, leveraging its established healthcare platform and physician network.